Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors

Biochimie

Volumn 92, Issue 11, 2010, Pages 1587-1596

  Olson, Steven T ^a   Richard, Benjamin ^a   Izaguirre, Gonzalo ^a   Schedin Weiss, Sophia ^b   Gettins, Peter G W ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anticoagulants; Antithrombin; Blood coagulation proteinases; Heparin; Serpins

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 9A; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; PENTASACCHARIDE; SERINE PROTEINASE INHIBITOR; THROMBIN;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; ANTICOAGULANT THERAPY; ANTICOAGULATION; CONFORMATIONAL TRANSITION; DRUG BINDING; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME MECHANISM; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STABILITY; ENZYME STRUCTURE; MOLECULAR INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEINASE INHIBITION; REVIEW; SITE DIRECTED MUTAGENESIS;

ALLOSTERIC REGULATION; ANIMALS; ANTITHROMBINS; BLOOD COAGULATION; HEPARIN; HUMANS; PEPTIDE HYDROLASES; SERPINS;

EID: 78149358266     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.05.011     Document Type: Review

References (60)

1. Gettins P. Serpin structure, mechanism, and function. Chem. Rev. 2002, 102:4751-4803.
2. Huntington J.A. Shape-shifting serpins-advantages of a mobile mechanism. Trends Biochem. Sci. 2006, 31:427-435.
3. 1-antitrypsin to inhibit cathepsin proteases. Biochemistry 2002, 41:4998-5004.
4. Björk I., Olson S.T. Antithrombin. A bloody important serpin. Chemistry and Biology of Serpins 1997, 17-33. Plenum Press, New York. F.C. Church, D.D. Cunningham, D. Ginsburg, M. Hoffman, S.R. Stone, D.M. Tollefsen (Eds.).
5. Church F.C., Pike R.N., Tollefsen D.M., Buckle D.M., Ciaccia A.V., Olson S.T. Regulation of hemostasis by heparin-binding serpins. Molecular and Cellular Aspects of the Serpinopathies and Disorders of Serpin Activity 2007, 509-554. World Scientific Publishing, Singapore. G.A. Silverman, D.A. Lomas (Eds.).
6. Van Boven H.H., Lane D.A. Antithrombin and its inherited deficiency states. Semin. Hematol. 1997, 34:188-204.
7. Ishiguro K., Kojima T., Kadomatsu K., Nakayama Y., Takagi A., Suzuki M., Takeda N., Ito M., Yamamoto K., Matsushita T., Kusugami K., Muramatsu T., Saito H. Complete antithrombin deficiency in mice results in embryonic lethality. J. Clin. Invest. 2000, 106:873-878.
8. Gettins P.G.W., Olson S.T. Exosite determinants of serpin specificity. J. Biol. Chem. 2009, 284:20441-20445.
9. Gettins P.G.W., Olson S.T. Activation of antithrombin as a factor IXa and Xa inhibitor involves mitigation of repression rather than positive enhancement. FEBS Lett. 2009, 583:3397-3400.
10. Huntington J.A., Read R.J., Carrell R.W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000, 407:923-926.
11. Stratikos E., Gettins P.G.W. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 A and full insertion of the reactive center loop into b-sheet A. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:4808-4813.
12. Dementiev A., Dobo J., Gettins P.G.W. Active-site distortion is sufficient for proteinase inhibition by serpins. J. Biol. Chem. 2006, 281:3452-3457.
13. Marcum J.A., Atha D.H., Fritze L.M.S., Nawroth P.P., Stern D.M., Rosenberg R.D. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparin sulfate proteoglycan. J. Biol. Chem. 1986, 261:7507-7517.
14. De Agostini A.I., Watkins S.C., Slayter H.S., Youssoufian H., Rosenberg R.D. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J. Cell Biol. 1990, 111:1293-1304.
15. Petitou M., Casu B., Lindahl U. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie 2003, 85:83-89.
16. Olson S.T., Björk I., Bock S.C. Identification of critical molecular interactions mediating heparin activation of antithrombin. Trends Cardiovasc. Med. 2002, 12:198-205.
17. Olson S.T., Björk I., Sheffer R., Craig P.A., Shore J.D., Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J. Biol. Chem. 1992, 267:12528-12538.
18. Olson S.T., Björk I. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects. J. Biol. Chem. 1991, 266:6353-6364.
19. Bedsted T., Swanson R., Chuang Y.-J., Bock P.E., Björk I., Olson S.T. Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites. Biochemistry 2003, 42:8143-8152.
20. Carrell R.W., Stein P.E., Fermi G., Wardell M.R. Biological implications of a 3 Å structure of dimeric antithrombin. Structure 1994, 2:257-270.
21. Jin L., Abrahams J.P., Skinner R., Petitou M., Pike R.N., Carrell R.W. The anticoagulant activation of antithrombin by heparin. Proc. Natl. Acad. Sci. U.S.A 1997, 94:14683-14688.
22. Whisstock J.C., Pike R.N., Jin L., Skinner R., Pei X.Y., Carrell R.W., Lesk A.M. Conformational changes in serpins: II. The mechanism of activation of antithrombin by heparin. J. Mol. Biol. 2000, 301:1287-1305.
23. Meagher J.L., Olson S.T., Gettins P.G.W. Critical role of the linker region between helix D and strand 2A in heparin activation of antithrombin. J. Biol. Chem. 1999, 275:2698-2704.
24. Belzar K.J., Zhou A., Carrell R.W., Gettins P.G.W., Huntington J.A. Helix D elongation and allosteric activation of antithrombin. J. Biol. Chem. 2002, 277:8551-8558.
25. Pike R.N., Potempa J., Skinner R., Fitton H.L., McGraw W.T., Travis J., Owen M., Jin L., Carrell R.W. Heparin-dependent modification of the reactive center arginine of antithrombin and consequent increase in heparin binding affinity. J. Biol. Chem. 1997, 272:19652-19655.
26. Chuang Y.-J., Swanson R., Raja S.M., Olson S.T. Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. J. Biol. Chem. 2001, 276:14961-14971.
27. Chuang Y.-J., Swanson R., Raja S.M., Bock S.C., Olson S.T. The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin. Biochemistry 2001, 40:6670-6679.
28. Olson S.T., Chuang Y.-J. Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc. Med. 2002, 12:331-338.
29. Izaguirre G., Zhang W., Swanson R., Bedsted T., Olson S.T. Localization of an antithrombin exosite that promotes rapid inhibition of factors Xa and IXa dependent on heparin activation of the serpin. J. Biol. Chem. 2003, 278:51433-51440.
30. Izaguirre G., Olson S.T. Residues Tyr253 and Glu255 in strand 3 of b-sheet C of antithrombin are key determinants of an exosite made accessible by heparin activation to promote rapid inhibition of factors Xa and IXa. J. Biol. Chem. 2006, 281:13424-13432.
31. 1-proteinase inhibitor that specifically enhance the inhibiiton of factor Xa and factor IXa. J. Biol. Chem. 2009, 284:1550-1558.
32. Johnson D.J., Li W., Adams T.E., Huntington J.A. Antithrombin-S195A factor Xa-heparin structure reveals the mechanism of antithrombin activation. EMBO J. 2006, 25:2029-2037.
33. Johnson D.J.D., Langdown J., Huntington J.A. Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7 A structure of the ternary complex. Proc. Natl. Acad. Sci. U.S.A 2010, 107:645-650.
34. Li W., Johnson D.J.D., Esmon C.T., Huntington J.A. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat. Struc. Mol. Biol. 2004, 11:857-862.
35. Dementiev A., Petitou M., Herbert J.-M., Gettins P.G.W. The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity. Nat. Struc. Mol. Biol. 2004, 11:863-867.
36. Yang L., Manithody C., Olson S.T., Rezaie A.R. Contribution of basic residues of the autolysis loop to the substrate and inhibitor specificity of factor IXa. J. Biol. Chem. 2003, 278:25032-25038.
37. Manithody C., Yang L., Rezaie A.R. Role of basic residues of the autolysis loop in the catalytic function of factor Xa. Biochemistry 2002, 41:6780-6788.
38. Huntington J.A., McCoy A., Belzar K.J., Pei X.Y., Gettins P.G.W., Carrell R.W. The conformational activation of antithrombin. A 2.85 A structure of a fluorescein derivative reveals an electrostatic link between the hinge and heparin binding regions. J. Biol. Chem. 2000, 275:15377-15383.
39. Dela Cruz R.G., Jairajpuri M.A., Bock S.C. Disruption of a tight cluster surrounding tyrosine 131 in the native conformation of antithrombin III activates it for factor Xa inhibition. J. Biol. Chem. 2006, 281:31668-31676.
40. Langdown J., Belzar K.J., Savory W.J., Baglin T.P., Huntington J.A. The critical role of hinge-region expulsion in the induced-fit heparin binding mechanism of antithrombin. J. Mol. Biol. 2009, 386:1278-1289.
41. Arocas V., Bock S.C., Raja S.M., Olson S.T., Björk I. Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding. J. Biol. Chem. 2001, 276:43809-43817.
42. Desai U., Swanson R., Bock S.C., Björk I., Olson S.T. Role of Arg 129 in heparin binding and activation of antithrombin. J. Biol. Chem. 2000, 275:18976-18984.
43. Schedin-Weiss S., Desai U.R., Bock S.C., Gettins P.G.W., Olson S.T., Björk I. Importance of lysine 125 for heparin binding and activation of antithrombin. Biochemistry 2002, 41:4779-4788.
44. Arocas V., Bock S.C., Olson S.T., Björk I. The role of Arg46 and Arg47 of antithrombin in heparin binding. Biochemistry 1999, 38:10196-10204.
45. Schedin-Weiss S., Desai U.R., Bock S.C., Olson S.T., Björk I. Roles of N-terminal region residues Lys11, Arg13, and Arg24 of antithrombin in heparin recognition and in promotion and stabilization of the heparin-induced conformational change. Biochemistry 2004, 43:675-683.
46. B. Richard, S.T. Olson, unpublished observations.
47. Backovic M., Gettins P.G.W. Insight into the residues critical for antithrombin function from analysis of an expanded database of sequences that includes frog, turtle, and ostrich antithrombins. J. Proteome Res. 2002, 1:367-373.
48. Jairajpuri M.A., Lu A., Desai U., Olson S.T., Björk I., Bock S.C. Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation. J. Biol. Chem. 2003, 278:15941-15950.
49. Gettins P. Antithrombin III and its interaction with heparin. Comparison of the human bovine, and porcine proteins by H NMR spectroscopy. Biochemistry 1987, 26:1391-1398.
50. Monien B.H., Krishnasamy C., Olson S.T., Desai U.R. Importance of tryptophan 49 of antithrombin in heparin binding and conformational activation. Biochemistry 2005, 44:11660-11668.
51. Olson S.T., Srinivasan K.R., Björk I., Shore J.D. Binding of high affinity heparin to antithrombin III. Stopped flow kinetic studies of the binding interaction. J. Biol. Chem. 1981, 256:11073-11079.
52. Langdown J., Carter W.J., Baglin T.P., Huntington J.A. Allosteric activation of antithrombin is independent of charge neutralization or reversal in the heparin binding site. FEBS Lett. 2006, 580:4709-4712.
53. Desai U.R., Petitou M., Björk I., Olson S.T. Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin. J. Biol. Chem. 1998, 273:7478-7487.
54. Richard B., Swanson R., Olson S.T. The signature 3-O-sulfo group of the anticoagulant heparin sequence is critical for heparin binding to antithrombin but is not required for allosteric activation. J. Biol. Chem. 2009, 284:27054-27064.
55. Schedin-Weiss S., Richard B., Hjelm R., Olson S.T. Antiangiogenic forms of antithrombin specifically bind to the anticoagulant heparin sequence. Biochemistry 2008, 47:13610-13619.
56. Wardell M.R., Chang W.S.W., Bruce D., Skinner R., Lesk A.M., Carrell R.W. Preparative induction and characterization of L-antithrombin: a structural homologue of latent plasminogen activator Inhibitor-1. Biochemistry 1997, 36:13133-13142.
57. S. Schedin-Weiss, B. Richard, S.T. Olson, unpublished observations.
58. Johnson D.J.D., Huntington J.A. Crystal structure of antithrombin in a heparin-bound intermediate state. Biochemistry 2003, 42:8712-8719.
59. Hopkins P.C.R., Pike R.N., Stone S.R. Evolution of serpin specificity: cooperative interactions in the reactive-site loop sequence of antithrombin specifically restrict the inhibition of activated protein C. J. Mol. Evol. 2000, 51:507-515.
60. Olson S.T., Swanson R., Raub-Segall E., Bedsted T., Sadri M., Petitou M., Herault J.-P., Herbert J.-M., Björk I. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thromb. Haemostas 2004, 92:929-939.